The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: A mini-review

Thrombosis Research

Volumn 109, Issue SUPPL., 2003, Pages

  Gustafsson, David ^a   Elg, Margareta ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Melagatran; Pharmacodynamics; Pharmacokinetics; Thrombin inhibitor; Ximelagatran

Indexed keywords

AZETIDINE DERIVATIVE; DRUG DERIVATIVE; GLYCINE; MELAGATRAN; PRODRUG; SERINE PROTEINASE; THROMBIN; WARFARIN; XIMELAGATRAN;

BIOAVAILABILITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BINDING; DRUG EFFECT; DRUG POTENCY; FOOD INTAKE; GASTROINTESTINAL ABSORPTION; HEMOSTASIS; HUMAN; PH; PHARMACOKINETICS; PRIORITY JOURNAL; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS;

EID: 0037669041     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(03)00249-4     Document Type: Conference Paper

References (63)

1. Lehmann J. Hypoprothrombinaemia produced by methylene-bis-(hydroxycoumarin). Its use in thrombosis. Lancet. 1:1942;318.
2. Allen E.V., Barker N.W., Waugh L.M. A preparation from spoiled sweet clover (3, 3′-methylene-bis-(4-hydroxycoumarin)) which prolongs coagulation and prothrombin time of the blood: a clinical study. JAMA. 120:1942;1009-1015.
3. Hirsh J., Dalen J.E., Anderson D.R., Poller L., Bussey H., Ansell J.et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 119:2001;8S-21S. [Suppl].
4. Claeson G. Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system. Blood Coagul. Fibrinolysis. 5:1994;411-436.
5. Hauptmann J., Stürzebecher J. Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. Thromb. Res. 93:1999;203-241.
6. Sanderson P.E. Small, noncovalent serine protease inhibitors. Med. Res. Rev. 19:1999;179-197.
7. Jones D.M., Atrash B., Ryder H., Teger-Nilsson A.C., Gyzander E., Szelke M. Thrombin inhibitors based on ketone derivatives of arginine and lysine. J. Enzyme Inhib. 9:1995;43-60.
8. Teger-Nilsson A.C., Bylund R., Gustafsson D., Gyzander E., Eriksson U. In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor. Thromb. Res. 85:1997;133-145.
9. Gustafsson D., Elg M., Lenfors S., Börjesson I., Teger-Nilsson A.C. Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. Blood Coagul. Fibrinolysis. 7:1996;69-79.
10. Eriksson U.G., Renberg L., Bredberg U., Teger-Nilsson A.C., Regårdh C.G. Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug. Biopharm. Drug Dispos. 19:1998;55-64.
11. Thrombin inhibition in Myocardial Ischaemia (TRIM) Study Group A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Eur. Heart J. 18:1997;1416-1425.
12. Gustafsson D., Nyström J., Carlsson S., Bredberg U., Eriksson U., Gyzander E.et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb. Res. 101:2001;171-181.
13. Gustafsson D., Antonsson T., Bylund R., Eriksson U., Gyzander E., Nilsson I.et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb. Haemost. 79:1998;110-118.
14. Boström S.L., Hansson G.F.H., Kjaer M., Sarich T.C. Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin, on the endogenous thrombin potential in venous blood from healthy male subjects. Blood Coagul. Fibrinolysis. 2003;. [In press].
15. Sarich T.C., Wolzt M., Eriksson U.G., Mattsson C., Schmidt A., Elg S.et al. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J. Am. Coll. Cardiol. 41:2003;557-564.
16. Sarich T., Eriksson U., Mattsson C., Wolzt M., Frison L., Fager G.et al. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. Thromb. Haemost. 87:2002;300-305.
17. Nylander S., Mattsson C. Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action. Blood Coagul. Fibrinolysis. 14:2003;159-167.
18. Mattson C., Menschik-Lundin A., Nylander S., Gyzander E., Deinum J. Effects of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro. Thromb. Res. 104:2001;475-486.
19. Weitz J.I. New antithrombotic agents. Chest. 119:2001;95S-107S. [Suppl].
20. Mattsson C., Björkman J.A., Ulvinge J.C. Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in the canine model of coronary artery thrombolysis. Fibrinolysis Proteolysis. 11:1997;121-128.
21. Mattsson C., Björkman J.A., Abrahamsson T., Nerme V., Schatteman K., Leurs J.et al. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran). Thromb. Haemost. 87:2002;557-562.
22. Eriksson H., Eriksson U.G., Frison L., Hansson P.O., Held P., Holmström M.et al. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb. Haemost. 81:1999;358-363.
23. Eriksson H.et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J. Thromb. Haemost. 1:2003;41-47.
24. Eriksson B.I., Carlsson S., Halvarsson M., Risberg B., Mattsson C. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat. Thromb. Haemost. 78:1997;1404-1407.
25. Carlsson S., Elg M., Mattsson C. Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats. Thromb. Res. 107:2002;163-168.
26. Elg M., Gustafsson D., Deinum J. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb. Haemost. 78:1997;1286-1292.
27. Elg M., Gustafsson D., Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb. Res. 94:1999;187-197.
28. Mikulski A., Elg M., Gustafsson D. The effects of oral and intravenous direct thrombin inhibitors on the size of photochemically induced cortical infarction in rats. Thromb. Res. 101:2001;477-482.
29. Mehta J.L., Chen L., Nichols W.W., Mattsson C., Gustafsson D., Saldeen T.G. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. J. Cardiovasc. Pharmacol. 31:1998;345-351.
30. Scherstén F., Wahlund G., Carlsson S., Mattsson C., Grip L. Melagatran attenuates fibrin and platelet deposition in a porcine coronary artery over-stretch injury model. Blood Coagul. Fibrinolysis. 2003;. [In press].
31. Eriksson M., Larsson A., Saldeen T., Mattsson C. Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig. Thromb. Haemost. 80:1998;1022-1026.
32. Elg M., Humphries B., Carlsson S., Gustafsson D. A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats. Blood. 98:2001;47a.
33. Sarich T.C., Osende J.I., Eriksson U.G., Fager G.B., Eriksson-Lepkowska M., Ohlsson L.et al. Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis. J. Thromb. Haemost. 1:2003;999-1004.
34. Eriksson B.I., Arfwidsson A.-C., Frison L., Eriksson U.G., Bylock A., Kälebo P.et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb. Haemost. 87:2002;231-237.
35. Mutch N.J., Robbie L.A., Booth N.A. Human thrombi contain an abundance of active thrombin. Thromb. Haemost. 86:2001;1028-1034.
36. Becker D.L., Fredenburgh J.C., Stafford A.R., Weitz J.I. Molecular basis for the resistance of fibrin-bound thrombin to inactivation by heparin/serpin complexes. Adv. Exp. Med. Biol. 425:1997;55-66.
37. Bates S.M., Weitz J.I. The mechanism of action of thrombin inhibitors. J. Invasive Cardiol. 12(Suppl. F):2000;27-32.
38. Lebrazi J., Elalamy I., Samama M.M. The in vitro effects of melagatran on clot bound thrombin. Haemostasis. 30(Suppl. 1):2000;54.
39. Nilsson T., Sjöling-Ericksson A., Deinum J. The mechanism of binding of low-molecular-weight active site inhibitors to human alpha-thrombin. J. Enzyme Inhib. 13:1998;11-29.
40. Jackman M.P., Parry M.A., Hofsteenge J., Stone S.R. Intrinsic fluorescence changes and rapid kinetics of the reaction of thrombin with hirudin. J. Biol. Chem. 267:1992;15375-15383.
41. Klement P., Carlsson S., Rak J., Liao P., Vlasin M., Stafford A.et al. The benefit-to-risk profile of melagatran is superior to that of hirudin in rabbit arterial thrombosis prevention and bleeding models. J. Thromb. Haemost. 1(3):2003;587-594.
42. Hull R., Hirsh J., Jay R., Carter C., England C., Gent M.et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N. Engl. J. Med. 307:1982;1676-1681.
43. Saour J.N., Sieck J.O., Mamo L.A., Gallus A.S. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N. Engl. J. Med. 322:1990;428-432.
44. Fager G., Cullberg M., Eriksson-Lepkowska M., Frison L., Eriksson U.G. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. Clin. Pharmacol. Ther. 2003;. [In press].
45. Elg M., Carlsson S., Gustafsson D. Effects of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb. Res. 101:2001;145-157.
46. Elg M., Carlsson S., Gustafsson D. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anaesthetised rats and rabbits. Thromb. Res. 101:2001;159-170.
47. Elg M., Martinsson R., Carlsson S., Gustafsson D. Prolonged bleeding time induced by a direct thrombin inhibitor is reversed by recombinant factor VIIa in anesthetized rats pre-treated with lipopolysaccharide. Pathophysiol. Haemost. Thromb. 32(Suppl. 2):2002;131.
48. Eriksson U.G., Bredberg U., Hoffmann K.-J., Thuresson A., Gabrielsson M., Ericsson H.et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab. Dispos. 31:2003;294-305.
49. Johansson L.C., Frison L., Logren U., Fager G., Gustafsson D., Eriksson U.G. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin. Pharmacokinet. 42:2003;381-392.
50. Sarich T.C., Teng R., Peters G.R., Wollbratt M., Homolka R., Svensson M., Eriksson U.G. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor, ximelagatran. Clin. Pharmacol. 42:2003;485-492.
51. Johansson L.C., Andersson M., Fager G., Gustafsson D., Eriksson U.G. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran, following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clin. Pharmacokin. 42:2003;475-484.
52. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 26(Suppl. 2):1996;24-38.
53. Dunn C.J., Jarvis B. Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease. Drugs. 60:2000;203-237.
54. Andersson T.B. Activation of ximelagatran, melagatrans prodrug. Drug Metab. Rev. 33(Suppl. 1):2001;8. [Abstract No. 14].
55. Eriksson-Lepkowska M., Thuresson A., Bylock A., Frison L., Eriksson U.G. The effect of the oral direct thrombin inhibitor, ximelagatran (pINN, formerlyH 376/95), on the pharmacokinetics and pharmacodynamics of diclofenac in healthy male volunteers. Thromb. Haemost. 2001;. [Suppl (July) (ISSN 0340-6245). Abstract No. P786].
56. Eriksson B.I., Bergqvist D., Kälebo P., Dahl O.E., Lindbratt S., Bylock A., Frison L., Eriksson U.G., Welin L., Gustafsson D. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet. 360:2002;1441-1447.
57. Johansson S., Bylock A., Eriksson-Lepkowska M., Thuresson A., Frison L., Eriksson U.G. The effect of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), on the pharmacokinetics of nifedipine, in healthy male volunteers. Thromb. Haemost. 2001;. [Suppl (July) (ISSN 0340-6245). Abstract No. P784].
58. Eriksson U.G., Mandema J.W., Karlsson M.O., Frison L., Olsson Gisleskog P., Wählby U.et al. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving sc melagatran and oral ximelagatran: a population model analysis. Clin. Pharmacokinet. 2003;. [In press].
59. Heit J.A., Colwell C.W., Francis C.W., Ginsberg J.S., Berkowitz S.D., Whipple J.et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch. Intern. Med. 161:2001;2215-2221.
60. Eriksson B.I.et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. The METHRO III study. Thromb. Haemost. 89:2003;288-296.
61. Francis C.W., Davidson B.L., Berkowitz S.D., Lotke P.A., Ginsberg J.S., Lieberman J.R.et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann. Intern. Med. 137:2002;648-655.
62. Petersen P.et al. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J. Am. Coll. Cardiol. 41:2003;1445-1451.
63. Ximelagatran compared with warfarin for the prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives and design of a pair of clinical trials and baseline patient characteristics (SPORTIF III and V). Am. Heart J. 2003;. [In press].